GIVAX, Inc.

3/10Traction

This company develops oral vaccines targeting gastrointestinal diseases like rotavirus and norovirus, primarily for children and adults. Their platform allows for rapid adaptation of vaccine antigens to match circulating strains of pathogens, enabling more effective protection against evolving GI illnesses.

HQ unknown

Founded 202113500+ followers

Biotechnology

Updated 5 months ago

Funding

Funding rounds are not available yet.

Founders

1 founder

Mario Barro

CEO

Product

Problem

Gastrointestinal (GI) illnesses, such as those caused by rotavirus and norovirus, pose a significant health burden, particularly for children and older adults. Current preventative measures are often limited in scope and effectiveness against the rapidly evolving strains of these viruses. This results in frequent outbreaks and substantial healthcare and economic costs globally.

Solution

GIVAX is developing a novel class of GI vaccines using a rotavirus-based vector platform to address the limitations of existing vaccines. By manipulating the rotavirus genome, GIVAX can express vaccine antigens targeting multiple GI pathogens, including rotavirus and norovirus. This platform enables rapid adaptation of vaccine antigens to match circulating strains, offering a more flexible and effective approach to GI disease prevention. The oral vaccine aims to induce mucosal immunity in the GI tract, which is crucial for protecting the pediatric population. GIVAX's approach has the potential to significantly reduce the global burden of GI illnesses.

Target Audience

The primary target audiences are children and adults at risk of contracting rotavirus, norovirus, and other gastrointestinal diseases, as well as public health organizations seeking to reduce the incidence and severity of GI outbreaks.

Features

Novel oral replicating rotavirus vector for safe and effective GI vaccines
Pediatric vector based on licensed vaccines with an established safety profile
Adult vector has demonstrated clinical safety
Ability to induce de-novo mucosal immunity in the GI tract
Flexible platform allows for easy updates to antigen composition to match circulating strains without changing manufacturing processes
Dual rotavirus/norovirus vaccine for pediatrics
Norovirus vaccine for adults
Potential for vaccines targeting other gastrointestinal pathogens, such as _Clostridioides difficile (C. Diff)_